Inflammatory Bowel Disease and the Risk of Herpes Zoster

Lai, Shih‐Wei

doi:10.5009/gnl19141

Cited by 2 publications

(2 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In our meta-analysis, we estimated that the attributable risk of developing herpes zoster related to inflammatory bowel disease was 4.31 per 1000 person-years in our meta-analysis. As mentioned in previous articles, [24,25] inflammatory bowel disease cannot be preventable or curable, but herpes zoster can be preventable by vaccination. Live vaccines are generally contraindicated in patients with immunosuppressive status, [14,26] The CDC suggests that a live attenuated herpes zoster vaccine is contraindicated in patients on a substantially immunosuppressive steroid dose ≥2 weeks of daily receipt of 20 mg or 2 mg/kg body weight of prednisone or equivalent [27] .…”

Section: Discussionmentioning

confidence: 95%

The incidence rate of herpes zoster in inflammatory bowel disease

et al. 2021

Self Cite

View full text Add to dashboard Cite

Inflammatory bowel disease is associated with an increased risk of opportunistic infections. This study aimed to investigate the incidence rate of herpes zoster in patients with inflammatory bowel disease.A meta-analysis was conducted by searching PubMed literature published from January 2000 to July 2019. The main outcome was the incidence rate of a new diagnosis of herpes zoster in patients previously diagnosed with inflammatory bowel disease. The incidence rate ratio (IRR) and 95% confidence interval (95% CI) for herpes zoster associated with inflammatory bowel disease was measured.A total of 6 eligible cohort studies matching the entry criteria were included in the meta-analysis, providing 216,552 participants with inflammatory bowel disease and 790 events of herpes zoster among these participants with inflammatory bowel disease. The pooled incidence rate of developing herpes zoster was 10.41 per 1000 person-years in the inflammatory bowel disease group and 6.10 per 1000 person-years in the non-inflammatory bowel disease group, respectively. The meta-analysis demonstrated that patients with inflammatory bowel disease were associated with 1.68-fold increased risk of developing herpes zoster when compared to those without inflammatory bowel disease (IRR = 1.68, 95% CI = 1.53-1.84). Crohn disease and ulcerative colitis were associated with an increased risk of developing herpes zoster (IRR = 1.67, 95% CI = 1.40-1.98 for Crohn disease and IRR = 1.49, 95% CI = 1.34-1.65 for ulcerative colitis, respectively).Patients with inflammatory bowel disease are at increased risk of developing herpes zoster. We suggest that the vaccination should be considered at the time of inflammatory bowel disease being diagnosed.

show abstract

Section: Discussionmentioning

confidence: 95%

The incidence rate of herpes zoster in inflammatory bowel disease

et al. 2021

Self Cite

View full text Add to dashboard Cite

show abstract

“…5‐aminosalicylic acid (5‐ASA), corticosteroid, and thiopurines (azathioprine and mercaptopurine) are widely used as antiinflammatory and immunosuppressive drugs for UC treatment (Damião et al, 2019). However, some UC patients receive temporary remission and have adverse reactions such as gastrointestinal reactions, hepatotoxicity, and nephrotoxicity (Lai, 2019). Therefore, alternative and novel treatment strategies should be explored.…”

Section: Introductionmentioning

confidence: 99%

Therapeutic potential of isobavachalcone, a natural flavonoid, in murine experimental colitis by inhibiting NF‐κB p65

Zhou

Zhong

Min

et al. 2021

Phytotherapy Research

View full text Add to dashboard Cite

The incidence of ulcerative colitis (UC), one of the two types of inflammatory bowel disease, is increasing in many countries. Various natural products have been demonstrated with therapeutic potentials for UC. Herein, the therapeutic effects and mechanisms of isobavachalcone (IBC), a natural chalcone, were evaluated in dextran sulfate sodium (DSS)-induced colitis mice and lipopolysaccharide (LPS)-stimulated RAW264.7 macrophages. The results demonstrated that IBC treatment significantly improved the clinical symptoms, assessed by the disease activity index (DAI) scores and the histological changes of the colon. The levels of myeloperoxidase (MPO), TNF-α, IL-6, IL-1β, and prostaglandin E2 (PGE2) in colon tissues were suppressed by IBC. The upregulation of inducible nitric oxide synthase (iNOS), cyclooxygenase-2 (COX-2), and NF-κB p65 in colon tissues were reversed by IBC as well. Furthermore, IBC significantly inhibited LPS-triggered secretion of TNF-α, IL-6, and nitrite, and nuclear translocation of NF-κB p65, in RAW264.7 cells. The luciferase reporter assay indicated that IBC significantly inhibited LPS-triggered transcription of toll-like receptor 4 (TLR4). Molecular docking results showed that the binding pocket of IBC was adjacent to Ser276 of p65-p50 heterodimer and IBC could form H-bond with Thr191. Collectively, these results demonstrated that IBC ameliorated colitis in mice possibly through inhibition of NF-κB p65.

show abstract

Inflammatory Bowel Disease and the Risk of Herpes Zoster

Cited by 2 publications

References 5 publications

The incidence rate of herpes zoster in inflammatory bowel disease

The incidence rate of herpes zoster in inflammatory bowel disease

Therapeutic potential of isobavachalcone, a natural flavonoid, in murine experimental colitis by inhibiting NF‐κB p65

Contact Info

Product

Resources

About